Aquestive Therapeutics (AQST) Cash from Investing Activities (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Cash from Investing Activities of -$52000.0 for Q1 2026, up 61.48% year-over-year from -$32201.8 in Q1 2025, and up 38.82% quarter-over-quarter from -$85000.0 in Q4 2025.
Aquestive Therapeutics (AQST) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$52000.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 61.48% year-over-year to -$52000.0; the TTM figure through Mar 2026 stood at -$479000.0 (down 80.75% YoY), while the FY2025 annual figure was -$562000.0, down 253.46% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$52000.0, up from -$85000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$2000.0 in Q1 2023, with the low at -$1.7 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is -$85000.0 (2025), against an average of -$252470.6.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 1968.67% in 2022, then surged 98.08% in 2023.
- Aquestive Therapeutics' Cash from Investing Activities stood at -$26000.0 in 2022, then surged by 38.46% to -$16000.0 in 2023, then advanced by 6.25% to -$15000.0 in 2024, then plunged by 466.67% to -$85000.0 in 2025, then soared by 38.82% to -$52000.0 in 2026.
- Business Quant data shows AQST's Cash from Investing Activities at -$52000.0 in Q1 2026, -$85000.0 in Q4 2025, and -$235000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | -212,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -212,000.00 |
| Jun 30, 2026 | -212,000.00 |
| Mar 31, 2026 | -52,000.00 |
| Mar 31, 2026 | -52,000.00 |
| Dec 31, 2025 | -85,000.00 |
| Dec 31, 2025 | -85,000.00 |
| Sep 30, 2025 | -235,000.00 |
| Sep 30, 2025 | -235,000.00 |
| Jun 30, 2025 | -107,000.00 |
| Jun 30, 2025 | -107,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -35,000.00 |
| Jun 30, 2024 | -35,000.00 |
| Mar 31, 2024 | -29,000.00 |
| Mar 31, 2024 | -29,000.00 |